Cyclosporine in uveitis: a game changer or a risky choice? A systematic review and meta-analysis of its efficacy and safety
British Journal of Ophthalmology · 2026-01 · 110 (1) · 8-16
DOI: 10.1136/bjo-2025-327349 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift British Journal of Ophthalmology, online erschienen am 14.08.2025. Verfasst von Kai Yang Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Chang Gung Memorial Hospital (Linkou branch), Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Cyclosporine, Uveitis, Immunosuppressive Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Background
Uveitis, an inflammation of the uveal tract, can lead to severe ocular complications and vision loss if left untreated. Cyclosporine has gained recognition as an effective immunosuppressive therapy, particularly as a steroid-sparing agent. This study aims to evaluate the efficacy and safety of cyclosporine in managing various types of uveitis, assess its safety profile and associated adverse effects, and compare its therapeutic effectiveness to other treatment options.
Methods
Systematic review and meta-analysis were conducted on PubMed, Science Direct, Dimensions and Google Scholar databases through 7 February 2025. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed, and the Population, Intervention, Comparison, Outcomes, Study Design framework was observed with the inclusion criteria. Eligible studies included randomised controlled trials, cohort studies and case series that assessed cyclosporine use for any form of uveitis. Outcomes included improvement in visual acuity, inflammation control, remission rates and adverse events (nephrotoxicity, hypertension, fatigue). Risk of bias was assessed using the Cochrane RoB 2 tool for Randomized Control Trials and Risk of Bias for the Non-Randomized Interventional studies for non-randomised studies. Quality was evaluated using the Joanna Briggs Institute Critical Appraisal Checklist for case–control studies for case series studies evaluation, and Newcastle-Ottawa Scale for cohort studies.
Results
A total of 57 703 studies were identified through database searching. After removal of duplicates and application of inclusion and exclusion criteria, 16 studies encompassing 943 patients were included in the final analysis. The meta-analysis demonstrated that cyclosporine therapy resulted in significant visual acuity improvement or stabilisation in approximately 79% of patients (event rate=0.879; 95% CI 0.832 to 0.914; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Medicine, Chang Gung Memorial Hospital (Linkou branch), Taoyuan, Taiwan.
- Department of Ophthalmology, China Medical University, Taichung, Taiwan.
- Department of Ophthalmology, Fu Jen Catholic University College of Medicine, New Taipei, Taiwan m212092001@tmu.edu.tw 068268@mail.fju.edu.tw.
- Department of Ophthalmology, Cardinal Tien Hospital, Xindian District, Taiwan.
Zitieren
APA
Chen, K. Y., Chan, H. C., & Chan, C. M. (2026). Cyclosporine in uveitis: a game changer or a risky choice? A systematic review and meta-analysis of its efficacy and safety. British Journal of Ophthalmology, 110(1), 8-16. https://doi.org/10.1136/bjo-2025-327349
Vancouver
Chen KY, Chan HC, Chan CM. Cyclosporine in uveitis: a game changer or a risky choice? A systematic review and meta-analysis of its efficacy and safety. British Journal of Ophthalmology. 2026;110(1):8-16. doi:10.1136/bjo-2025-327349
BibTeX
@article{Chen2026,
author = {Chen, Kai Yang and Chan, Hoi-Chun and Chan, Chi Ming},
title = {Cyclosporine in uveitis: a game changer or a risky choice? A systematic review and meta-analysis of its efficacy and safety},
journal = {British Journal of Ophthalmology},
year = {2026},
volume = {110},
number = {1},
pages = {8--16},
doi = {10.1136/bjo-2025-327349}
}
EUVIMED